Tempus AI Stock Surges as Analyst Confidence Grows

Tempus AI shares are gaining significant momentum after financial firm BTIG substantially raised its price target from $96 to $105 while maintaining its buy recommendation. The artificial intelligence specialist continues to demonstrate powerful growth drivers, consistently exceeding elevated market expectations.

Quarterly Performance Exceeds Projections

Earlier in November, Tempus AI delivered an impressive third-quarter earnings surprise. The company reported a loss per share of just -$0.11, significantly better than the anticipated -$0.18 loss. Revenue climbed to $334.2 million, surpassing the $328.7 million forecast.

The company’s expansion continues at a remarkable pace, with year-over-year revenue growth reaching 84.7%. Following these strong results, management upgraded its full-year guidance to approximately $1.265 billion, representing growth of roughly 80%.

Analyst Sees Substantial Upside Potential

BTIG analysts have expressed increased confidence in Tempus AI’s sustainable growth trajectory following discussions with the company’s CFO and investor relations team. Their bullish stance rests on several key factors:

• Core operations in data and pharmaceutical services remain strong and well-diversified
• The Ambry acquisition is performing more than 20% above expectations
• The algorithm segment promises long-term gross margins exceeding 80%

Despite the stock’s 125% annual gain, Tempus AI trades at a moderate 2026 price-to-earnings ratio of 8.2, representing a discount to the industry average of 10.4.

Should investors sell immediately? Or is it worth buying Tempus AI?

Regulatory Approvals Fuel Innovation Pipeline

Two significant FDA clearances highlight Tempus AI’s ongoing technological advancement. In September, the company received 510(k) clearance for its AI-powered cardiac MRI platform, Tempus Pixel. This followed July’s authorization for ECG software designed to detect heart failure.

The strategic $81.25 million acquisition of Paige in August further strengthens the company’s digital pathology capabilities—a crucial competency for expanding its multimodal dataset.

Technical Indicators Show Mixed Signals

Since reaching a turning point on November 20, the stock has advanced 17%. While short-term moving averages suggest buying opportunities, longer-term technical signals remain negative. Immediate resistance levels appear at $82.32, with support expected around $70.16.

The average analyst price target currently stands at $80 with a hold recommendation, though recent revisions show a clear upward trend. The next significant test for the company will come with fourth-quarter results in February 2026.